What will changes to the Sunshine Act mean for devicemakers?

Medical device manufacturers could soon be looking at additional expenses following proposed changes to the Physician Payment Sunshine Act. The changes were proposed by the Centers for Medicare & Medicaid Services (CMS) and are designed to correct certain unintended consequences of the current text and make policy consistent with that of the drug and biologics industries. The most notable change for devicemakers, said law firm King and Spalding, would be reporting the names of all products associated with a particular payment. Companies would be forced to make "significant and expensive upgrades" to their data systems to accommodate the new policies. The changes are slated to take effect Jan. 1, 2015, and would impact data collection for 2014. Story

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.